Regeneron will receive a $30 million upfront payment and is eligible to receive up to $160 million in additional regulatory and sales milestones, the companies said in a statement.
The Regeneron-Zai Lab collaboration will also support enrollment of regional patients into Regeneron's global trials assessing REGN1979 in B-cell non-Hodgkin lymphoma (B-NHL), the companies said.
REGN1979 is designed to trigger tumor killing by linking and activating a cytotoxic T-cell to a lymphoma cell, according to the statement.
Price: 501.51, Change: -2.76, Percent Change: -0.55
|Consensus for Zumiez Q2 Earnings Raised but Full Yea...|
|Williams Sonoma's Q2, 2021, 2022 Full Year Earnings ...|
|Analysts' Ratchet Up 2020, 2021 Consensus Estimates ...|
|Q1, 2021, 2022 Earnings Estimates for Advanced Drain...|
|Q2 Projection for Westlake Chemical Increased but 20...|